Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepaStem for acute-on-chronic liver failure
NL-OMON55256Phase 2Not yet recruiting
- Sponsor
- Promethera Therapeutics
- Start
- Sep 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute-on-chronic liver failure (ACLF) comparing HepaStem with Placebo (2 arms). Primary endpoint: Overall survival at Day 90. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
hepastem
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NL-OMON55256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55256.